Alcidion Group Limited · ASX:ALC
Alcidion — Investor Presentation (March 2025)
37 slides from Alcidion's investor presentation, Mar 12, 2025
Slide 1: Investor Roadshow Presentation
12 March 2025 Australian Securities Exchange 20 Bridge Street Sydney NSW 2000 Investor Roadshow Presentation Melbourne, Victoria | Alcidion Group Limited (ASX:ALC) Alcidion CEO and Managing Director, Kate Quirke will be attending a number of meetings with potential investors in Sydney over March 12
Slide 2: Investor Presentation: Accelerating Growth
For personal use only Investor Presentation ACCELERATING GROWTH MARCH 2025
Slide 3: Disclaimer
Disclaimer The information contained in this document (“Document”) has been prepared by Alcidion Group Limited ACN 143 142 any change in expectations in relation to any such statements or any change in events, conditions or circumstances 410 (referred to as “Alcidion” or “Company”). This Document is
Slide 4: Alcidion: ready for rapid scaling, best-in-class
Alcidion: ready for rapid scaling, best-in-class Healthcare software and informatics company For personal use only revolutionising efficiency and quality of care Best-in-class, Australian- 100+ clinical Strong balance sheet, Highly experienced team Compelling platform made healthcare implementations
Slide 5: What is Miya Precision?
What is Miya Miya Precision is a data platform for healthcare. However, it is more than that - Miya Precision digitises the clinical workflow and Precision? provides the foundation for the application of AI capability in healthcare. For personal use only Designed for AI Miya Precision has been desig
Slide 6: Smarter Solutions for Clinicians
Smarter Solutions for Clinicians Solutions For personal use only Powering Smarter Care At the core of Alcidion’s solutions Patient Flow Emergency Modular EPR Virtual Care Integrated is our FHIR-based interoperability & Command Emergency Modular cloud- Virtual care and Care Record platform for smarte
Slide 7: Expanding Market Share Health Services
Expanding Market Share 108 Health Services For personal use only AU$2bn global market opportunity 447 Health Services 100+ clinical system implementations 28 Health Services In the past three months, Alcidion has signed major deals with 2 health services in Victoria (AU), one in South Australia (AU)
Slide 8: Challenges in Healthcare
For personal use only 02. Challenges in Healthcare SMARTER SOLUTIONS FOR CLINICIANS
Slide 9: The Opportunity in Australia
The Opportunity in Australia There continues to be opportunity in the Australian market to improve data For personal use only interoperability, health system transparency, and enable the future of patient care. 9
Slide 10: Opportunities with the NHS
Opportunities with the NHS For personal use only The NHS continues to face digitisation challenges, with older technology plaguing efforts to modernise the health system. 10
Slide 11: Miya: Solving Problems
Miya: Solving Problems For personal use only Integrating Digitising Clinical the Care Record Workflow Creating the longitudinal record for Deploying digital tools to improve every patient, in every setting. efficiency, accuracy, and patient care. Releasing Health Scaling Remote System Capacity Patie
Slide 12: Miya: Solving Problems - Integrating the Care Record
Miya: Solving Problems Integrating the Care Record Aged Care Healthcare digital solutions have grown organically Remote Fragmented For personal use only for the last 30-40 years. As an example, Health NZ Monitoring patient data report having 6000 systems in their ecosystem. Emergency Clinician prefe
Slide 13: Miya: Solving Problems - Digitising Clinical Workflow
Miya: Solving Problems Digitising Clinical Workflow Paper-based processes increase the likelihood Clinical Errors and For personal use only of medication errors, missed allergies, and Patient Safety Risks communication failures between care teams. Siloed information across departments and Fragmented
Slide 14: Miya: Solving Problems - Scaling Remote Patient Monitoring
Miya: Solving Problems Scaling Remote Patient Monitoring Hospitals Hospitals are overwhelmed, making it Miya Care app over capacity essential to shift lower-risk cases to home care. For personal use only Pressure to reduce Home-based care can be cost of care cheaper than inpatient hospital stays. St
Slide 15: Miya: Solving Problems - Releasing Health System Capacity
Miya: Solving Problems Releasing Health System Capacity Hospitals over Health systems frequently report operating at occupancy capacity levels of ~120%. Corridor care For personal use only is on the rise Often patients turn to emergency rooms because Shortage of GPs they lack access to primary care
Slide 16: Product and Impact
For personal use only 03. Product and Impact POSITIONED FOR GROWTH
Slide 17: The modular Miya Precision platform
The modular Miya Precision platform real time analytics icon resolve icon graph icon hospital icon eye icon Real Time Analytics Predictive Analytics Outlier Resolution Capacity Management Discharge Barriers For personal use only highly extensible icon peak icon barrier icon Hospital at a Glance Pati
Slide 18: Case Study: Alfred Health
Case Study: Alfred Health Independent Study on Miya Precision Benefits In 2023, Alfred Health introduced electronic patient journey boards (EPJBs) to 38 inpatient wards at The Alfred, Caufield and Sandringham hospitals. As part of the deployment, the Digital Health CRC & Monash University were engag
Slide 19: For an 800-bed healthcare system
For an 800-bed healthcare system For personal use only Released Released Released Non- Released Released Nursing Time Physician Time clinical Time Capacity Operational Cost How much 321,235 408,220 27,397 35,375 3,002,125 capacity have hours hours hours bed days documents we released? (165 FTEs) (20
Slide 20: Progress. Profitability. Growth.
For personal use only 04. Progress. Profitability. Growth. FINANCIAL OVERVIEW
Slide 21: H1 FY25 Executive Summary
H1 FY25 Executive Summary For personal use only $17.6M $18.3M $61.3M $39.5M $0.5M H1 FY25 revenue H1 New TCV2 sales FY25 YTD New TCV sales FY25 contracted revenue Underlying H1 EBITDA3 Down 7% on pcp1,as Includes both contracted Highest new TCV signed in Includes Hywel Dda Material improvement expec
Slide 22: H1 FY25 Executive Summary (cont.)
H1 FY25 Executive Summary (cont.) For personal use only › Peninsula Health (AUS): Miya Precision deployment; TCV of $3.7M over 5 years › North Adelaide Local Health Network (AUS): Miya Precision & mobile clinical comms solutions; $4.5M TCV over 5 years New › Hume Rural Health Alliance (AUS): Miya Pr
Slide 23: Revenue Dashboard
Revenue Dashboard 40.4 37.1 H1 vs H2 34.4 Geographical For personal use only Revenue 25.9 21.4 Split (%) 18.0 Split ($M) 21.5 17.6 43% 14.8 $17.6M Total 57% 19.0 19.1 17.6 UK ANZ 11.1 12.9 FY21 FY22 FY23 FY24 H1'25 H1 H2 40.4 37.1 Revenue 34.4 10.0 Recurring 29% 22% 7.5 Category 6.2 (product) Total
Slide 24: Notable Contract Wins & Renewals
Notable Contract Wins & Renewals New contracts reinforce modular strategy, catering to needs of customers as they enhance their digital maturity For personal use only Hume Rural Health Alliance (AUS) Hywel Dda (Wales) › TCV of $4.0m over 5 years › TCV of $5.5M over 5 years (with 2-year option › Miya
Slide 25: EPR Validation: North Cumbria
EPR Validation: North Cumbria Signed contract with North Cumbria Integrated Care NHS Foundation Trust (NCIC) for new EPR platform solution For personal use only Contract Signed - Overview Key Contract Terms › Selected following a competitive tender process › Deploy Miya Precision encompassing full s
Slide 26: Successful Deployments in H1 FY25
Successful Deployments in H1 FY25 Product Implementation and technical service delivery have always been a strength of the Alcidion business For personal use only Hume Rural Health Alliance (AUS) Hampshire Hospitals NHS Foundation Trust › First site went ‘live’ in late Oct-24 › First deployment of M
Slide 27: Profitability
For personal use only 05. Profitability STRONG OUTLOOK AND GROWTH POTENTIAL
Slide 28: Bright Path Ahead
Bright Path Ahead FY25 contracted revenue signed to date will result in full year revenue growth (vs. FY24) and positive EBITDA and cashflow For personal use only Current FY25 contracted Confident of delivering Strong momentum building revenue of $39.5M a positive EBITDA and for our solutions across
Slide 29: Investment Highlights
Investment Highlights For personal use only Large Addressable Market Strong Financial Profile Strong Marquee Customers › 146 Acute UK NHS Trusts; ALC with foothold › $39.5M current contracted & renewal › $37.5M over 10 years with North Cumbria in only ~27% revenue to be recognised in FY25 for Miya P
Slide 30: Corporate Snapshot
For personal use only 06. Corporate Snapshot ALCIDION CORPORATE OVERVIEW
Slide 31: Corporate Snapshot
Corporate Snapshot For personal use only ASX:ALC Trading Information Share Price (10 March 2025) $0.083 12-month Low / High $0.044 - $0.115 12-month average daily liquidity ($) $125k Shares outstanding 1,343 million Market Capitalisation $111m Cash (31 Dec 2024) $7.7m Debt (31 Dec 2024) Nil Enterpri
Slide 32: The Alcidion Board
The Alcidion Board For personal use only Rebecca Wilson Kate Quirke Victoria Weekes Daniel Sharp Will Smart Chair Group Managing Director/ Non-executive Director Non-executive Director Non-executive Director Chief Executive Officer Experienced company director with 25+ years of digital health sector
Slide 33: Appendix
For personal use only 07. Appendix ADDITIONAL FINANCIAL INSIGHT
Slide 34: Profit & Loss
Profit & Loss Annually recurring product revenue expected to increase in future periods as benefits of contracts signed in H1 are recognised, underpinning confidence in future profitability For personal use only Profit & loss (A$000) H1'24 H1'25 % change Recurring Product - M&S + Annual Licences 14,
Slide 35: Balance Sheet
Balance Sheet For personal use only Balance sheet ($000) 30-Jun-24 31-Dec-24 › $7.7m cash and no debt 1 Cash & cash equivalents 11,798 7,681 as of 31 December 2024 Trade & other receivables 5,214 9,759 2 › Trade receivables increased over prior year, Other assets 1,527 1,645 underpinning historicall
Slide 36: Cashflow
Cashflow For personal use only Cash flow ($000) 1H'24 1H'25 Receipts from customers 15,105 15,342 Payments to suppliers & employees (26,505) (19,481) Income tax paid - - Interest received 30 57 Finance costs (52) (40) › H1 FY25 operating cash flows 1 Cash (outflow) from operating activities (11,422)
Slide 37: For personal use only
For personal use only